Barclays’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-21,000
Closed -$779K 5440
2024
Q3
$779K Buy
+21,000
New +$703K ﹤0.01% 3517
2020
Q2
Sell
-100
Closed -$4K 6113
2020
Q1
$4K Sell
100
-202,800
-100% -$10.2M ﹤0.01% 5968
2019
Q4
$9.74M Buy
202,900
+50,600
+33% +$2.15M 0.01% 1422
2019
Q3
$5.15M Buy
152,300
+98,000
+180% +$4.27M ﹤0.01% 1827
2019
Q2
$2.44M Buy
54,300
+54,200
+54,200% +$2.14M ﹤0.01% 2672
2019
Q1
$4K Sell
100
-400
-80% -$13.4K ﹤0.01% 6759
2018
Q4
$17K Hold
500
﹤0.01% 5976
2018
Q3
$24K Sell
500
-22,100
-98% -$914K ﹤0.01% 6415
2018
Q2
$762K Sell
22,600
-167,600
-88% -$5.23M ﹤0.01% 3547
2018
Q1
$5.15M Buy
190,200
+190,100
+190,100% +$4.82M ﹤0.01% 1618
2017
Q4
$2K Buy
+100
New +$1.69K ﹤0.01% 6791
2017
Q2
Sell
-141,000
Closed -$1.39M 6871
2017
Q1
$1.39M Buy
+141,000
New +$1.71M ﹤0.01% 2426
2016
Q1
Sell
-190,900
Closed -$6.11M 6380
2015
Q4
$6.11M Sell
190,900
-911,100
-83% -$26.8M 0.01% 1180
2015
Q3
$28.7M Buy
1,102,000
+993,800
+918% +$42.5M 0.03% 443
2015
Q2
$5.19M Buy
108,200
+58,900
+119% +$3.44M 0.01% 1460
2015
Q1
$2.96M Buy
+49,300
New +$3.01M ﹤0.01% 1969

Other funds holding PTCT

Barclays's PTCT Position: Q2 2026 in Review

Barclays increased its PTC Therapeutics (PTCT) stake by 10% in Q2 2026, buying an estimated $382K and bringing the position to 58,370 shares worth $4.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1875.

Barclays first reported a position in PTCT in Q3 2013 and has held it in 52 quarters since. The position peaked at $16.7M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Barclays held 58,370 shares of PTC Therapeutics worth $4.76M as of Q2 2026.
  • Barclays bought 5,291 PTC Therapeutics shares in Q2 2026, an estimated $382K.
  • PTC Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1875 holding.
  • Barclays first reported a position in PTC Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Barclays's PTC Therapeutics position peaked at $16.7M in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.